MedPath

Oshkosh Defense Submits Proposal for Robotic Combat Vehicle (RCV) Phase II

• Oshkosh Defense has submitted its proposal for the U.S. Army's Robotic Combat Vehicle (RCV) Phase II program, aiming to provide innovative technologies for enhanced soldier performance. • The Oshkosh RCV is designed to be modular and payload agnostic, allowing for rapid integration of future technologies and adaptability in multi-domain operations. • Oshkosh delivered two RCV Platform Prototypes in August 2024 as part of Phase I, supporting mobility testing and soldier feedback for Phase II selection. • Phase II, valued at $118.9 million, requires contractors to deliver nine RCV Production Representative Prototypes by early 2026.

Oshkosh Defense, LLC, a business of Oshkosh Corporation, announced its submission of a proposal on August 29, 2024, for the U.S. Army’s Robotic Combat Vehicle (RCV) Phase II: Production Representative Prototype (PRP) program. The proposal responds to the Army’s Request for Prototype Proposal (RPP).
"At Oshkosh Defense, we design with the future in mind," stated Pat Williams, chief programs officer at Oshkosh Defense. "Our offering for Phase II of the RCV program leverages our engineering expertise to provide the U.S. Army with innovative, adaptable technologies to enhance Soldier performance and mission success."
The Oshkosh RCV is purpose-built to equip soldiers with the capabilities needed for increased performance, improved maintainability, and flexibility in multi-domain operations. Developed through multiple iterations of testing and soldier feedback, the modular Oshkosh RCV is payload agnostic, supporting the rapid integration of future technologies. Oshkosh’s systems engineering approach and design maturity aim to ensure the U.S. Army achieves program milestones within the Rapid Prototype phase of this Mid-Tier Acquisition.

Prototype Delivery and Collaboration

On August 19, 2024, Oshkosh delivered two RCV Platform Prototypes as part of the Phase I Ground Vehicle Systems (GVS) Other Transaction Agreement (OTA) awarded in September 2023. These prototypes support platform mobility testing and soldier touchpoints as part of the Phase II source selection process.
"The Oshkosh team, with Pratt Miller Defense and QinetiQ US, has applied early feedback to deliver prototypes and a Phase II proposal that are soldier-centered and designed to keep pace with the evolving battlefield," Williams added. "We remain steadfast in our collaboration with the U.S. Army to provide the most capable, mature, and production-ready RCV offering to achieve the program’s rapid prototype and fielding schedule."

Phase II Details

Phase II consists of a base award of $118.9 million. Down-selected contractors are required to deliver nine RCV Production Representative Prototypes in early 2026.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

© Copyright 2025. All Rights Reserved by MedPath